Effector Therapeutics Inc Financial Flexibility Index
Effector Therapeutics Inc financial flexibility index. Effector Therapeutics Inc (EFTR) has a Financial Flexibility Index of -0.28x as of March 2024. Free cash flow of $-7.28 Million (operating CF $-7.28 Million minus capex $0.00) represents 0% of total liabilities ($26.30 Million). See Effector Therapeutics Inc (EFTR) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Effector Therapeutics Inc (2019–2023)
Financial flexibility index of Effector Therapeutics Inc from 2019 to 2023. Historical Financial Flexibility Index trend for Effector Therapeutics Inc across 5 annual periods. Check EFTR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Effector Therapeutics Inc Financial Flexibility Index by Year (2019–2023)
Effector Therapeutics Inc financial flexibility index by year from 2019 to 2023. Year-by-year free cash flow to debt coverage for Effector Therapeutics Inc. For the full cash flow conversion analysis, see Effector Therapeutics Inc operating cash flow efficiency.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2023 | -1.12x | $-29.45 Million | $-29.55 Million | $26.34 Million | ▼ -9.5% |
| 2022 | -1.02x | $-25.71 Million | $-25.90 Million | $25.18 Million | ▼ -51.1% |
| 2021 | -0.68x | $-24.85 Million | $-24.89 Million | $36.77 Million | ▼ -819.4% |
| 2020 | 0.09x | $13.99 Million | $13.84 Million | $148.95 Million | ▲ +106.4% |
| 2019 | -1.46x | $-27.59 Million | $-27.60 Million | $18.93 Million | — |